Daratumumab, an anti-CD38 monoclonal antibody, has been approved for the treatment of multiple myeloma. Data are needed regarding the use of daratumumab for high-risk smoldering multiple myeloma ...

Participants received CD68-ET3-LV–transduced autologous CD34+ HSCs at doses of 5.0×10 6 to 6.1×10 6 per kilogram of body weight. The vector copy numbers in the final drug product were 1.0 and ...

B-cell acute lymphoblastic leukemia (B-cell ALL) is the most common childhood cancer. Despite a high overall cure rate, relapsed B-cell ALL remains a leading cause of cancer-related death among ...